Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes

Psychotherapy and Psychosomatics

Volumn 77, Issue 2, 2008, Pages 69-77

  Chouinard, Guy ^a   Chouinard, Virginie Anne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LEVODOPA; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; PLACEBO; PROLACTIN; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

AKATHISIA; ANXIETY DISORDER; DEPRESSION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EDITORIAL; EPIDEMIOLOGICAL DATA; HUMAN; IATROGENIC DISEASE; INCIDENCE; MAINTENANCE THERAPY; MOOD DISORDER; MOTOR DYSFUNCTION; PANIC; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REBOUND; REBOUND PSYCHOSIS; RELAPSE; REMISSION; SCHIZOPHRENIA; SUPERSENSITIVITY; SUPERSENSITIVITY REBOUND PSYCHOSIS; TARDIVE DYSKINESIA; WITHDRAWAL SYNDROME;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; HUMANS; IATROGENIC DISEASE; INCIDENCE; MENTAL DISORDERS; PREVALENCE; PSYCHOSES, SUBSTANCE-INDUCED; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 38649128497     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112883     Document Type: Editorial

References (89)

1. Falloon IR: Antipsychotic drugs: when and how to withdraw them? Psychother Psychosom 2006;75:133-138.
2. Fava GA: Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry 2003;64:123-133.
3. Lambert TJ: Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry 2007;68:10-13.
4. Chouinard G, Annable L, Ross-Chouinard A, Mercier P: A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988;8(suppl):S21-S26.
5. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
6. ISCTM Third Annual Mid-Year Conference. Brussels, 17-18 September 2007.
7. Morrens M, Hulstijn W, Sabbe B: Psychomotor slowing in schizophrenia. Schizophr Bull 2007;33:1038-1053.
8. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R: Tardive dyskinesia in the era of typical and atypical antipsychotics. 1. Pathophysiology and mechanisms of induction. Can J Psychiatry 2005;50:541-547.
9. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
10. Chouinard G: New nomenclature for druginduced movement disorders including tardive dyskinesia. J Clin Psychiatry 2004;65(suppl):S9-S15.
11. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
12. Chouinard G, Albright PS: Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997;17:298-307.
13. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P: Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15:917-926.
14. Chouinard G, Arnott W: Clinical review of risperidone. Can J Psychiatry 1993;38 (suppl 3):S89-S95.
15. Chouinard G, Kopala L, Labelle A, Beauclair L, Johnson SV, Singh KI: Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group. Can J Psychiatry 1998;43:1018-1025.
16. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-546.
17. Moller HJ, Muller H, Borison RL, Schooler NR, Chouinard G: A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995;245:45-49.
18. 2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999;156:876-884.
19. Margolese HC, Chouinard G, Beauclair L, Belanger MC: Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2002;22:347-352.
20. Chouinard G, Margolese HC: Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76:247-265.
21. Chouinard G, Boisvert D, Bradwejn J: Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug. Can Med Assoc J 1982;126:821-822, 827.
22. Chouinard G, Jones BD: Early onset of tardive dyskinesia: case report. Am J Psychiatry 1979;136:1323-1324.
23. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L: Tardive dyskinesia in the era of typical and atypical antipsychotics. 2. Incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005;50:703-714.
24. Chouinard G, Steinberg S: Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:571-578.
25. Chouinard G, Annable L, Ross-Chouinard A, Nestoros JN: Factors related to tardive dyskinesia. Am J Psychiatry 1979;136:79-82.
26. Ghadirian AM, Annable L, Belanger MC, Chouinard G: A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry 1996;57:22-28.
27. Chouinard G: Interrelations between psychiatric symptoms and drug-induced movement disorder. J Psychiatry Neurosci 2006;31:177-180.
28. Barnes TR, Kidger T, Gore SM: Tardive dyskinesia: a 3-year follow-up study. Psychol Med 1983;13:71-81.
29. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J: Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22:254-258.
30. Yassa R, Jeste DV: Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18:701-715.
31. Kane JM, Smith JM: Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473-481.
32. Chouinard G: Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15(suppl 1):S36-S44.
33. Chouinard G, Lasser R, Bossie C, Zhu Y, Gharabawi G: Does a long-acting atypical antipsychotic offer a low risk of tardive dyskinesia in patients with schizophrenia? Schizophr Res 2003;60:277.
34. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (Inter-SePT). Arch Gen Psychiatry 2003;60:82-91.
35. Chouinard G, Margolese H, Alphs L, Larach-Walters V, Beauclair L, Anand R: Relationship between baseline extrapyramidal symptoms and suicidality in schizophrenic subjects included in the InterSePT trial. Biol Psychiatry 2002;51(suppl):S20-S21.
36. Chouinard G, Bhanji NH, Light M, Margolese HC: Patient characteristics, symptom severity, and movement disorders in patients with schizophrenia and schizoaffective disorder. Biol Psychiatry 2003;53(suppl):S21.
37. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-425.
38. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA: Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157:1150-1155.
39. Kane JM: Tardive dyskinesia circa 2006. Am J Psychiatry 2006;163:1316-1318.
40. Kay SR, Opler LA, Lindenmayer JP: The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 1989;7:59-67.
41. Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23:99-110.
42. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, Wright P, Knapp M: The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003;107:222-232.
43. Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS, Lieberman JA: Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005;80:33-43.
44. Tenback DE, van Harten PN, Slooff CJ, van Os J: Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Compr Psychiatry 2007;48:436-440.
45. Tenback DE, van Harten PN, Slooff CJ, van Os J: Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 2006;163:1438-1440.
46. Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J: Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. J Clin Psychiatry 2005;66:1130-1133.
47. Tenback DE, van Harten PN, Slooff CJ, van Os J: Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances. Neuropsychopharmacology 2006;31:1832-1837.
48. Ghadirian AM, Chouinard G, Annable L: Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982;170:463-467.
49. Van Putten T, Mutalipassi LR, Malkin MD: Phenothiazine-induced decompensation. Arch Gen Psychiatry 1974;30:102-105.
50. Van Putten T, May RP: 'Akinetic depression' in schizophrenia. Arch Gen Psychiatry 1978;35:1101-1107.
51. Rifkin A, Quitkin F, Klein DF: Akinesia: a poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry 1975;32:672-674.
52. Margolese HC, Chouinard G, Walters-Larach V, Beauclair L: Relationship between antipsychotic-induced akathisia and tardive dyskinesia and suicidality in schizophrenia: impact of clozapine and olanzapine. Acta Psychiatr Belg 2001;101:128-144.
53. Chouinard G, Jones BD, Annable L: Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 1978;135:1409-1410.
54. Chouinard G, Jones BD: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 1980;137:16-21.
55. Chouinard G, Annable L, Ross-Chouinard A: Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. Psychopharmacol Bull 1986;22:891-896.
56. Chouinard G, Creese I, Boisvert D, Annable L, Bradwejn J, Jones B: High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. Biol Psychiatry 1982;17:849-852.
57. Chouinard G, Bradwejn J, Annable L, Jones BD, Ross-Chouinard A: Withdrawal symptoms after long-term treatment with low-potency neuroleptics. J Clin Psychiatry 1984;45:500-502.
58. Kales A, Scharf MB, Kales JD: Rebound insomnia: a new clinical syndrome. Science 1978;201:1039-1041.
59. Fontaine R, Chouinard G, Annable L: Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am J Psychiatry 1984;141:848-852.
60. Chouinard G: Rebound anxiety: incidence and relationship to subjective cognitive impairment. J Clin Psychiatry Monogr 1986;4:12-16.
61. Bhanji NH, Chouinard G, Kolivakis T, Margolese HC: Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena. Can J Clin Pharmacol 2006;13:e69-e74.
62. Chouinard G: Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 2004;65(suppl 5):7-12.
63. Fava GA, Bernardi M, Tomba E, Rafanelli C: Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007;10:835-838.
64. Chouinard G: Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 1991;5:21-33.
65. Moncrieff J: Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem. Med Hypotheses 2006;67:517-523.
66. Moncrieff J: Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 2006;114:3-13.
67. Fava M, Schmidt ME, Zhang S, Gonzales J, Raute NJ, Judge R: Treatment approaches to major depressive disorder relapse. 2. Reinitiation of antidepressant treatment. Psychother Psychosom 2002;71:195-199.
68. Baldessarini RJ, Ghaemi SN, Viguera AC: Tolerance in antidepressant treatment. Psychother Psychosom 2002;71:177-179.
69. Schmidt ME, Fava M, Zhang S, Gonzales J, Raute NJ, Judge R: Treatment approaches to major depressive disorder relapse. 1. Dose increase. Psychother Psychosom 2002;71:190-194.
70. Shoenberger D: Discontinuing paroxetine: a personal account. Psychother Psychosom 2002;71:237-238.
71. Chouinard G, Jones B: Neuroleptic-induced supersensitivity psychosis, the 'hump course' and tardive dyskinesia (letter). J Clin Psychopharmacol 1982;2:143-144.
72. Chouinard G, Annable L, Ross-Chouinard A: Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect. Am J Psychiatry 1982;139:312-318.
73. Miller R, Chouinard G: Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993;34:713-738.
74. 2 high dopamine receptors. Synapse 2006;60:319-346.
75. Chouinard G, Annable L, Ross-Chouinard A, Holobow N: A ten year follow-up of supersensitivity psychosis. Biol Psychiatry 1990;27:110A.
76. 2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-369.
77. Ekblom B, Eriksson K, Lindstrom LH: Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology (Berl) 1984;83:293-294.
78. Miller R: A Theory of the Basal Ganglia and Their Disorders. Boca Raton, CRC Press, 2008.
79. Llorca PM, Vaiva G, Lancon C: Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal. Can J Psychiatry 2001;46:87-88.
80. Chouinard G, Sultan S: Treatment of neuroleptic-induced supersensitivity psychosis with antiepileptic drugs: report of a series of 43 cases. Psychopharmacol Bull 1990;26:337-341.
81. Citrome L, Jaffe A, Levine J, Allingham B: Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatr Serv 2002;53:1212.
82. Kremer I, Vass A, Gorelik I, Bar G, Blanaru M, Javitt DC, Heresco-Levy U: Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004;56:441-446.
83. Dursun SM, McIntosh D, Milliken H: Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry 1999;56:950.
84. Chouinard G, Beauclair L, Belanger MC: Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry 1998;43:305.
85. Goldberg JF, Burdick KE: Cognitive side effects of anticonvulsants. J Clin Psychiatry 2001;62(suppl 14):S27-S33.
86. Large CH, Webster EL, Goff DC: The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl) 2005;181:415-436.
87. Zipp F, Burklin F, Stecker K, Baas H, Fischer PA: Lamotrigine in Parkinson's disease - a double blind study. J Neural Transm Park Dis Dement Sect 1995;10:199-206.
88. Kolivakis TT, Beauclair L, Margolese HC, Chouinard G: Long-term lamotrigine adjunctive to antipsychotic monotherapy in schizophrenia: further evidence. Can J Psychiatry 2004;49:280.
89. Malhotra AK, Murphy GM Jr, Kennedy JL: Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004;161:780-796.